This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
1 Feb 2011

Alexion Announces $111M Acquisition of Taligen

Alexion Pharmaceuticals bought privately held biotechnology firm Taligen Therapeutics for $111 million, to expand its product portfolio.

Alexion Pharmaceuticals announced its acquisition of Taligen Therapeutics, a privately held development-stage biotechnology company. The $111 million acquisition broadens Alexion’s list of product candidates and expands Alexion’s capabilities in translational medicine by bringing in additional researchers.
 
Taligen has a number of preclinical compounds, including potential treatments for patients with ophthalmic diseases such as age-related macular degeneration (AMD), as well as other novel antibody and protein regulators of the complement inflammatory pathways.

Related News

  • News Swiss pharma industry warns US tariffs could harm global patient care

    The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.

  • News Understanding the Benefits and Advances of Cleanroom Technology

    In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?

  • News From Pharma to Table? Direct-to-consumer pharma sales and price cuts ramp up in US

    The pharmaceutical industry is witnessing a seismic shift as major companies embrace direct-to-consumer sales models and announce significant price reductions across the United States, responding to mounting pressure from the Trump administration to ta...
  • News A Day in the Life of a Director of Business Development

    In this Day in the Life of interview, Thomas Hauser, Director of Business Development at Tjoapack. Thomas has spent nearly 30 years in the pharmaceutical industry and describes how he still finds curiosity and excitement in the bigger picture of global...
  • News Women in Pharma: Our hopes for 2025 and beyond

    Our last instalment for 2024 of the Women in Pharma series brings you messages direct from the Informa Markets CPHI team as they discuss the advice and insights they have carried throughout their roles working at CPHI, and what they hope to see for the...
  • News CPHI Milan 2024 - From the Floor

    Milan and CPHI welcome you to 2024 CPHI Milan! As we celebrate the 35th edition of our flagship CPHI show, editors Vivian Xie and Lucy Chard bring you the latest from the show floor, conference sessions, and innovative solutions from all exhibitors, at...
  • News The BIOSECURE Act: implications for the pharma supply chain

    On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin...
  • News A Day in the Life of a Global CDMO Chapter Lead – Manufacturing

    The 'Day in the Life of' series has covered many aspects of the pharmaceutical pipeline, including R&D and procurement, now we're taking a look at manufacturing from a global CDMO perspective.